metformin has been researched along with Cystadenocarcinoma, Serous in 3 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Cystadenocarcinoma, Serous: A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin is an oral anti-diabetic drug of the biguanide family used for treatment of type 2 diabetes." | 1.39 | Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners. ( Attias-Geva, Z; Bruchim, I; Fishman, A; Friedman, Y; Sarfstein, R; Werner, H, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Insin, P | 1 |
| Prueksaritanond, N | 1 |
| Sarfstein, R | 1 |
| Friedman, Y | 1 |
| Attias-Geva, Z | 1 |
| Fishman, A | 1 |
| Bruchim, I | 1 |
| Werner, H | 1 |
| Ezewuiro, O | 1 |
| Grushko, TA | 1 |
| Kocherginsky, M | 1 |
| Habis, M | 1 |
| Hurteau, JA | 1 |
| Mills, KA | 1 |
| Hunn, J | 1 |
| Olopade, OI | 1 |
| Fleming, GF | 1 |
| Romero, IL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Association Between Diabetes Mellitus, Oral Lichen Planus and Insulin-like Growth Factors 1 and 2 (IGF1 and IGF2)[NCT03257228] | 24 participants (Actual) | Observational | 2014-11-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 other studies available for metformin and Cystadenocarcinoma, Serous
| Article | Year |
|---|---|
Therapeutic Use of Metformin in Diabetes and Survival Outcomes in Endometrial Cancer Patients with Diabetes
Topics: Adenocarcinoma, Clear Cell; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Diabetes Mellitus, Typ | 2018 |
Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners.
Topics: Adenylate Kinase; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell S | 2013 |
Association of Metformin Use with Outcomes in Advanced Endometrial Cancer Treated with Chemotherapy.
Topics: Adenocarcinoma, Clear Cell; Aged; Carcinosarcoma; Cystadenocarcinoma, Serous; Endometrial Neoplasms; | 2016 |